Quel est le prix pour Apexigen, Inc. (APGN)

Le prix pour Apexigen, Inc. (APGN) est $0.385

Quelle est la capitalisation boursière pour Apexigen, Inc. (APGN)

La capitalisation boursière pour Apexigen, Inc. (APGN) est $2.86M

Apexigen, Inc. (APGN) Actions en Circulation

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Année	Actions en circulation	Changez
Pas assez de données pour les dates fournies.

Année

Actions en circulation

Changez

Pas assez de données pour les dates fournies.

Entreprise	Actions en circulation	Différence	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-	BE

Entreprise

Actions en circulation

Différence

Pays